Latest Period
Q1 2026
Security Snapshot
ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) Institutional Ownership
CUSIP: 29251M106
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
131
Shares (Excl. Options)
26,772,664
Price
$12.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ENTA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 26,772,664
- Total 13F value
- $338,104,430
- Portfolio coverage rank
- 0%
- Share change
- +442,038
- Value change
- +$2,308,887
- Number of holders
- 131
- Shares outstanding
- 28,862,345
- SEC-reported price per share
- $13.45
- Insider filing price
- $13.45
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ENTA - ENANTA PHARMACEUTICALS INC - Common Stock is tracked under CUSIP 29251M106.
- 131 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 130 to 131 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $416,082,980 to $338,104,430.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 131 institutions filings for Q1 2026.
Security key
29251M106
Latest holder period
Q1 2026
13F holders
131
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
ENTA full holder history
ENANTA PHARMACEUTICALS INC SEC filings
ENANTA PHARMACEUTICALS INC company facts
ENANTA PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29251M106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ENTA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | $41,823,994 | 3,494,068 | JANUS HENDERSON GROUP PLC | 31 Oct 2025 | |||
| Farallon Capital Partners, L.P. | 9.8% | -1% | $44,421,914 | +$11,174,622 | 2,816,862 | +34% | Dapice Joshua J. | 31 Dec 2025 |
| Deep Track Capital, LP | 6.8% | +29% | $25,263,153 | +$6,098,090 | 1,956,867 | +32% | Deep Track Capital, LP | 31 Dec 2025 |
| Luly Jay R. | 7.7% | $9,659,503 | 1,703,616 | Jay R. Luly, Ph.D. | 12 Feb 2025 | |||
| BlackRock, Inc. | 7.8% | $9,488,649 | 1,673,483 | BlackRock, Inc. | 31 Mar 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 2.3% | -45% | $10,572,650 | -$7,381,243 | 670,428 | -41% | Millennium Management LLC | 31 Dec 2025 |
As of 31 Mar 2026, 131 institutional investors reported holding 26,772,664 shares of ENANTA PHARMACEUTICALS INC - Common Stock (ENTA). This represents 93% of the company’s total 28,862,345 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 13% | 3,784,055 | +1.5% | 0.02% | $47,716,934 |
| BlackRock, Inc. | 11% | 3,103,768 | +0.89% | 0% | $39,200,591 |
| FARALLON CAPITAL MANAGEMENT LLC | 10% | 2,871,862 | +3.6% | 0.24% | $36,271,617 |
| Krensavage Asset Management, LLC | 9.9% | 2,866,138 | +3.6% | 14% | $36,199,000 |
| Deep Track Capital, LP | 6.8% | 1,956,867 | 0% | 0.51% | $24,715,230 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 1,178,049 | 0% | 0% | $14,878,759 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.3% | 948,904 | 0% | 0% | $11,984,658 |
| Spruce Street Capital LP | 3.2% | 932,598 | +139% | 2.8% | $11,778,713 |
| MILLENNIUM MANAGEMENT LLC | 3.1% | 882,097 | +32% | 0.01% | $11,140,885 |
| ACADIAN ASSET MANAGEMENT LLC | 3% | 880,023 | -0.58% | 0.02% | $11,102,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 725,061 | +12% | 0% | $9,159,559 |
| RENAISSANCE TECHNOLOGIES LLC | 2.3% | 665,258 | +3.6% | 0.01% | $8,402,209 |
| STATE STREET CORP | 1.9% | 562,106 | +7.3% | 0% | $7,099,399 |
| Hillsdale Investment Management Inc. | 1.5% | 435,510 | +3.1% | 0.15% | $5,500,491 |
| AQR CAPITAL MANAGEMENT LLC | 1.1% | 313,157 | +33% | 0% | $3,955,173 |
| MORGAN STANLEY | 1.1% | 309,511 | -8.9% | 0% | $3,909,132 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1% | 294,971 | +35% | 0% | $3,725,484 |
| TWO SIGMA INVESTMENTS, LP | 0.93% | 267,364 | -6.3% | 0% | $3,376,807 |
| GOLDMAN SACHS GROUP INC | 0.92% | 265,088 | +21% | 0% | $3,348,062 |
| CITADEL ADVISORS LLC | 0.91% | 262,533 | +182% | 0% | $3,315,791 |
| NORTHERN TRUST CORP | 0.83% | 240,968 | +4.8% | 0% | $3,043,426 |
| MARSHALL WACE, LLP | 0.73% | 210,070 | -45% | 0% | $2,653,185 |
| DIMENSIONAL FUND ADVISORS LP | 0.7% | 203,252 | -4% | 0% | $2,566,230 |
| Invesco Ltd. | 0.63% | 182,002 | -28% | 0% | $2,298,685 |
| VANGUARD FIDUCIARY TRUST CO | 0.61% | 175,856 | 0% | 0% | $2,221,061 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,772,664 | $338,104,430 | +$2,308,887 | $12.63 | 131 |
| 2025 Q4 | 26,389,999 | $416,082,980 | +$116,200,977 | $15.77 | 130 |
| 2025 Q3 | 18,990,953 | $227,099,660 | +$8,889,718 | $11.97 | 119 |
| 2025 Q2 | 18,415,589 | $139,218,163 | -$1,130,233 | $7.56 | 103 |
| 2025 Q1 | 18,625,766 | $102,810,306 | -$7,313,392 | $5.52 | 108 |
| 2024 Q4 | 19,907,432 | $114,464,576 | -$17,702,481 | $5.75 | 105 |
| 2024 Q3 | 21,229,862 | $219,956,486 | -$10,189,778 | $10.36 | 110 |
| 2024 Q2 | 22,131,926 | $287,039,395 | -$4,639,003 | $12.97 | 99 |
| 2024 Q1 | 22,403,789 | $391,166,955 | +$45,279,493 | $17.46 | 105 |
| 2023 Q4 | 20,026,111 | $188,441,196 | -$5,171,233 | $9.41 | 103 |
| 2023 Q3 | 20,144,110 | $225,005,701 | -$8,699,698 | $11.17 | 129 |
| 2023 Q2 | 19,936,779 | $426,629,256 | -$15,765,200 | $21.40 | 129 |
| 2023 Q1 | 19,836,693 | $802,018,224 | +$23,678,858 | $40.44 | 142 |
| 2022 Q4 | 19,243,859 | $895,247,833 | -$44,744,222 | $46.52 | 145 |
| 2022 Q3 | 19,726,320 | $1,023,129,229 | -$26,641,297 | $51.87 | 155 |
| 2022 Q2 | 20,231,748 | $956,338,910 | +$17,270,558 | $47.27 | 149 |
| 2022 Q1 | 19,671,490 | $1,399,487,075 | +$60,693,984 | $71.18 | 163 |
| 2021 Q4 | 18,780,733 | $1,403,536,269 | -$51,376,670 | $74.78 | 172 |
| 2021 Q3 | 19,379,501 | $1,101,045,074 | +$34,578,566 | $56.81 | 140 |
| 2021 Q2 | 18,825,846 | $828,634,567 | -$26,899,911 | $44.01 | 147 |
| 2021 Q1 | 19,430,818 | $956,710,887 | +$7,403,943 | $49.32 | 146 |
| 2020 Q4 | 19,261,435 | $811,015,243 | +$16,262,569 | $42.10 | 148 |
| 2020 Q3 | 18,857,563 | $863,147,048 | +$27,242,369 | $45.78 | 170 |
| 2020 Q2 | 18,268,221 | $917,098,781 | +$10,521,228 | $50.21 | 173 |
| 2020 Q1 | 18,020,619 | $927,779,000 | -$32,712,586 | $51.43 | 154 |